Format

Send to

Choose Destination
Biol Psychiatry. 2006 Jan 15;59(2):97-105. Epub 2005 Sep 2.

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.

Author information

1
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA. richard.keefe@duke.edu

Abstract

BACKGROUND:

Neurocognitive deficits are severe in first-episode psychosis.

METHODS:

Patients (N = 263) with first-episode psychosis (schizophrenia, schizoaffective, or schizophreniform disorders) were randomly assigned to double-blind treatment with olanzapine (mean 11.30 mg/day) or haloperidol (mean 4.87 mg/day) for 104 weeks. A neurocognitive battery was administered at baseline (n = 246) and 12 (n = 167), 24 (n = 126), 52 (n = 89), and 104 (n = 46) weeks during treatment. Weighted principal component and unweighted composite scores were derived from individual tests.

RESULTS:

Both treatment groups demonstrated significant improvement on both composite scores. On the basis of the weighted composite score, olanzapine had greater improvement than haloperidol only at 12 (p = .014) and 24 (p = .029) weeks. For the unweighted composite, olanzapine had significantly better improvement compared with haloperidol only at week 12 (p = .044). At week 12 only, olanzapine improved performance on the Digit Symbol and Continuous Performance Test significantly more than haloperidol.

CONCLUSIONS:

Both antipsychotic agents appeared to improve neurocognitive functioning among first-episode psychosis patients with schizophrenia. A significantly greater benefit in terms of neurocognitive improvement was found with olanzapine than with haloperidol at weeks 12 and 24.

PMID:
16140282
DOI:
10.1016/j.biopsych.2005.06.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center